human
adenoviru
hadv
viremia
known
common
allogen
hematopoiet
cell
transplant
hct
recipi
particularli
children
incid
hadv
viremia
follow
allogen
hct
report
children
adult
although
variabl
studi
report
hadv
infect
includ
viremia
usual
occur
within
first
day
endogen
reactiv
latent
viru
regard
major
mode
infect
howev
de
novo
infect
nosocomi
commun
set
could
also
mortal
approxim
howev
dissemin
case
rate
may
increas
major
risk
factor
sever
invas
hadv
diseas
dissemin
deplet
includ
ex
vivo
deplet
use
alemtuzumab
younger
age
unrel
donor
graft
cord
blood
prolong
immunosuppress
treatment
absolut
lymphocyt
count
alc
addit
risk
background
european
societi
infecti
diseas
leukemia
recommend
routin
hadv
monitor
use
quantit
polymeras
chain
reaction
pcr
peripher
blood
especi
howev
correl
hadv
speci
clinic
featur
immunocompromis
popul
establish
yet
hadv
caus
varieti
clinic
manifest
depend
viru
type
tissu
tropism
immunocompet
host
exampl
speci
c
e
caus
respiratori
ill
wherea
speci
f
g
mainli
caus
gastroenter
speci
eg
hadv
respons
urinari
tract
infect
speci
b
known
associ
seriou
complic
often
result
lower
respiratori
tract
ill
particularli
associ
hadv
speci
b
hypothes
hadv
type
could
also
affect
clinic
featur
includ
sever
andor
dissemin
allogen
hct
recipi
main
object
studi
investig
epidemiolog
hadv
infect
clinic
correl
hadv
type
among
korean
pediatr
allogen
hct
recipi
addit
explor
potenti
risk
factor
hadv
infect
andor
viremia
mortal
studi
conduct
samsung
medic
center
smc
seoul
korea
april
septemb
consecut
pediatr
recipi
age
less
year
receiv
allogen
hct
pediatr
cancer
center
agre
particip
includ
inform
consent
assent
obtain
time
enrol
studi
approv
institut
review
board
irb
smc
irb
recipi
screen
respiratori
viru
infect
admiss
hct
center
enrol
patient
blood
urin
stool
specimen
collect
prospect
infus
date
transplant
day
ml
edta
whole
blood
collect
weekli
day
transplant
day
day
day
etc
urin
stool
sampl
collect
weekli
well
blood
sampl
collect
specimen
store
dna
extract
day
urin
stool
specimen
test
whenev
clinic
suspect
hadv
detect
perform
addit
quantit
pcr
use
blood
specimen
detect
hadv
viremia
respiratori
specimen
test
use
multiplex
respiratori
viru
pcr
lg
life
scienc
korea
respiratori
symptom
present
part
routin
care
practic
dna
extract
aliquot
clinic
sampl
use
qiaamp
blood
stool
mini
kit
qiagen
hilden
germani
elut
dna
store
pcr
amplif
quantit
pcr
use
detect
hadv
blood
specimen
use
commerci
adenoviru
kit
argen
varhil
franc
lower
limit
quantit
copiesml
qualit
convent
pcr
perform
detect
hadv
urin
stool
specimen
use
premix
kit
bioneer
daejeon
korea
follow
manufactur
protocol
human
adenoviru
type
determin
sequenc
region
hexon
gene
nest
pcr
perform
secur
suffici
hadv
dna
sequenc
use
previous
describ
method
minor
modif
method
sequenc
perform
direct
use
round
pcr
primer
softwar
gene
code
ann
arbor
mi
usa
basic
local
align
search
tool
blast
softwar
http
blastncbinlmnihgov
use
identifi
hadv
type
phylogenet
molecular
analys
conduct
use
mega
refer
hadv
strain
shown
tabl
epidemiolog
data
patient
characterist
includ
age
hct
sex
underli
diseas
type
donor
sourc
graft
use
total
bodi
irradi
tbi
use
atg
condit
regimen
collect
medic
record
time
enrol
perform
weekli
monitor
clinic
data
includ
symptom
laboratori
data
sever
diseas
gvhd
maxim
dose
system
corticosteroid
complic
day
mortal
medic
chart
review
patient
hadv
infect
clinic
data
includ
detail
treatment
also
review
defin
infect
caus
pathogen
addit
hadv
day
period
use
previous
propos
definit
hadv
infect
type
hadv
infect
occur
simultan
sequenti
terminolog
multipl
hadv
infect
use
defin
hadv
infect
identif
adenoviru
surveil
sampl
regardless
symptom
hadv
viremia
defin
posit
hadv
pcr
result
peripher
blood
local
hadv
infect
coliti
cystiti
respiratori
tract
infect
defin
posit
hadv
pcr
result
antigen
detect
correspond
bodi
fluid
peripher
blood
probabl
diseas
defin
hadv
infect
plu
correspond
symptom
sign
without
histolog
confirm
proven
diseas
defin
hadv
infect
plu
correspond
symptom
sign
histolog
condit
regimen
determin
primari
diseas
age
statu
accord
studi
protocol
high
gy
busulfan
mgkg
oral
dose
mgkg
intraven
dose
usual
employ
myeloabl
condit
regimen
depend
specif
protocol
patient
relaps
neuroblastoma
treat
ri
condit
regimen
vivo
deplet
use
alemtuzumab
ex
vivo
deplet
perform
center
calcineurin
inhibitor
alon
immunosuppress
mycophenol
mofetil
corticosteroid
methotrex
waswer
start
day
gvhd
prophylaxi
cord
blood
recipi
receiv
cyclosporin
csa
plu
mycophenol
mofetil
diagnos
acut
chronic
gvhd
base
standard
clinic
criteria
biopsi
perform
acut
gvhd
grade
ii
treat
system
corticosteroid
recipi
receiv
antivir
prophylaxi
acyclovir
day
day
antifung
prophylaxi
micafungin
day
neutrophil
engraft
pneumocysti
jirovecii
prophylaxi
trimethoprimsulfamethoxazol
neutrophil
engraft
cessat
immunosuppress
demograph
clinic
data
compar
use
fisher
exact
test
test
categor
variabl
u
test
continu
variabl
appropri
categor
variabl
present
frequenc
percentag
continu
variabl
summar
median
rang
logist
regress
analysi
perform
evalu
risk
factor
hadv
infect
viremia
relationship
potenti
risk
factor
outcom
test
cox
regress
variabl
p
univari
analysi
includ
multivari
analysi
model
also
includ
variabl
age
hct
sex
relaps
statu
underli
diseas
relaps
sever
acut
gvhd
grade
addit
multivari
analysi
model
ii
phylogenet
tree
gener
use
nj
method
accuraci
phylogenet
tree
test
bootstrap
replic
cumul
incid
hadv
infect
hadv
viremia
relationship
overal
surviv
hadv
infect
estim
use
method
assess
use
test
p
less
consid
statist
signific
statist
analys
perform
use
spss
version
spss
chicago
il
usa
graphpad
prism
version
graphpad
softwar
la
jolla
ca
usa
april
septemb
total
pediatr
recipi
receiv
allogen
hct
smc
among
recipi
hct
procedur
enrol
figur
median
age
hct
year
rang
year
recipi
male
median
year
rang
year
none
patient
receiv
ex
vivo
deplet
detail
characterist
list
tabl
total
blood
sampl
stool
sampl
urin
sampl
test
hadv
detect
sampl
recipi
tabl
cumul
incid
hadv
infect
day
year
year
confid
interv
ci
ci
ci
respect
figur
four
recipi
develop
hadv
viremia
cumul
incid
day
year
ci
ci
ci
respect
figur
median
time
hct
first
hadv
infect
day
rang
day
onset
hadv
viremia
day
rang
day
half
hadv
infect
occur
day
hct
respiratori
specimen
n
detect
day
tabl
among
patient
experienc
relaps
underli
diseas
one
patient
recipi
separ
episod
hadv
infect
patient
develop
hadv
diarrhea
without
viremia
day
hct
develop
anoth
episod
hadv
infect
hadv
detect
urin
blood
day
hct
perform
year
hct
ten
hadv
infect
probabl
hadv
diseas
asymptomat
infect
enter
diarrhea
melena
n
respiratori
ill
n
common
clinic
manifest
follow
hematuria
n
asymptomat
condit
n
tabl
among
patient
hadv
infect
patient
viremia
receiv
intens
immunosuppress
agent
due
extens
chronic
gvhd
wherea
patient
without
viremia
experi
extens
chronic
gvhd
p
two
patient
viremia
dissemin
hadv
infect
time
death
deceas
patient
suffer
progress
sever
hadv
pneumonia
persist
hadv
viremia
poorli
control
extens
chronic
gvhd
tabl
alc
patient
viremia
significantli
lower
patient
without
viremia
median
rang
vs
rang
p
among
total
sampl
sampl
avail
type
sequenc
repres
sampl
studi
tabl
among
hadv
commonli
detect
type
n
follow
hadv
n
one
case
hadv
respect
tabl
phylogenet
tree
hadv
shown
figur
type
analysi
hadv
type
detect
blood
variou
type
detect
stool
hadv
p
one
urin
specimen
type
hadv
tabl
note
differ
type
hadv
detect
sequenti
recipi
case
figur
one
patient
recipi
hadv
detect
blood
day
hadv
detect
stool
day
anoth
patient
recipi
hadv
detect
day
hadv
detect
day
stool
sampl
figur
univari
analysi
identifi
potenti
risk
factor
hadv
infect
tabl
case
hadv
viremia
n
extens
chronic
gvhd
identifi
risk
factor
univari
analysi
p
howev
unabl
appli
multivari
analysi
due
small
number
case
tabl
univari
analysi
categori
underli
diseas
relaps
state
underli
diseas
type
donor
intens
condit
regimen
use
atg
extens
chronic
gvhd
exist
hadv
viremia
identifi
potenti
risk
factor
mortal
p
hadv
viremia
appear
signific
risk
factor
mortal
univari
analysi
p
signific
multivari
analysi
model
ii
hazard
ratio
hr
ci
p
tabl
relaps
state
underli
diseas
hr
ci
p
extens
chronic
gvhd
hr
ci
p
identifi
signific
risk
factor
mortal
multivari
analysi
model
ii
tabl
overal
surviv
significantli
differ
among
recipi
hadv
infect
vs
recipi
without
hadv
infect
p
figur
describ
epidemiolog
hadv
infect
korean
allogen
hct
recipi
identifi
hadv
type
observ
hadv
viremia
patient
multipl
differ
hadv
type
site
result
studi
highlight
epidemiolog
find
differ
previou
studi
first
cumul
incid
hadv
viremia
lower
previou
studi
studi
cumul
incid
hadv
viremia
day
year
wherea
rate
report
previou
studi
pediatr
one
possibl
explan
use
alemtuzumab
ex
vivo
deplet
appli
center
deplet
use
reduc
gvhd
certain
center
also
major
risk
factor
hadv
infect
hct
recipi
associ
signific
immunosuppress
earli
therefor
use
less
intens
deplet
strategi
center
may
explain
lower
incid
hadv
viremia
especi
earli
second
onset
hadv
infect
appear
delay
studi
compar
result
previou
studi
previou
studi
includ
recipi
receiv
deplet
ex
vivo
deplet
report
major
hadv
infect
occur
day
associ
high
morbid
feuchting
et
conduct
prospect
studi
children
show
hadv
infect
viremia
occur
within
month
hct
lion
et
also
report
median
onset
day
hadv
detect
hct
day
rang
day
day
contrast
seven
hadv
infect
hadv
viremia
case
occur
day
studi
monitor
period
appli
accord
patient
immun
therefor
may
necessari
expand
regular
hadv
monitor
patient
delay
immun
reconstitut
predomin
hadv
type
allogen
hct
recipi
may
differ
accord
countri
andor
geograph
region
well
gener
popul
studi
hadv
n
identifi
preval
type
follow
hadv
n
contrast
previou
studi
mostli
conduct
european
countri
report
speci
c
hadv
type
order
frequenc
speci
hadv
preval
speci
among
pediatr
hct
commun
infect
set
hadv
identifi
preval
genotyp
uk
croatia
wherea
hadv
identifi
preval
type
result
type
analys
east
asian
countri
taiwan
japan
also
show
speci
b
especi
hadv
preval
hadv
c
well
known
persist
infect
mucos
lymphocyt
tissu
henc
hadv
c
may
like
latent
state
transplant
link
earli
reactiv
differ
preval
specif
viru
type
commun
might
one
possibl
explan
incid
hadv
infect
studi
lower
previou
studi
european
high
hadv
load
blood
known
import
risk
factor
diseas
sever
mortal
therefor
guidelin
recommend
quantit
pcr
monitor
hadv
peripher
addit
viral
load
also
question
whether
sever
clinic
manifest
rate
viremia
would
differ
accord
viru
type
viremia
case
caus
hadv
n
patient
die
condit
relat
dissemin
hadv
infect
taniguchi
et
report
dissemin
hadv
infect
occur
exclus
speci
b
recipi
hadv
recipi
one
recipi
respect
among
japanes
adult
recipi
haploident
hct
feghoul
et
report
surveil
data
french
pediatr
allogen
hct
recipi
suggest
speci
c
highli
virul
despit
preval
contrast
lion
et
report
fatal
case
associ
speci
c
among
austrian
pediatr
allogen
hct
recipi
relationship
hadv
type
clinic
sever
andor
dissemin
remain
uncertain
base
current
data
henc
studi
need
observ
interest
find
analys
first
differ
type
hadv
detect
recipi
within
short
time
interv
recipi
figur
second
type
hadv
detect
stool
differ
type
detect
blood
certain
patient
recipi
kroe
et
al
report
similar
result
data
pediatr
hct
recipi
among
recipi
multipl
hadv
type
detect
recipi
find
support
hypothesi
endogen
reactiv
latent
state
tissu
rather
consecut
hadv
infect
exogen
sourc
like
individu
find
need
interpret
caution
first
refus
particip
drop
rate
studi
period
high
major
reason
refus
enrol
poor
complianc
includ
difficulti
collect
deliv
urin
stool
specimen
second
possibl
underestim
incid
hadv
infect
viremia
due
fact
routin
surveil
perform
day
hct
found
signific
number
hadv
infect
occur
day
lastli
size
studi
sampl
rel
small
demonstr
definit
risk
factor
hadv
infect
viremia
summari
observ
lower
incid
rate
delay
onset
pattern
hadv
infect
previou
studi
might
influenc
extent
deplet
andor
local
hadv
epidemiolog
hadv
common
type
follow
hadv
wherea
hadv
report
preval
type
western
countri
although
unabl
identifi
potenti
risk
factor
hadv
infect
viremia
found
recipi
viremia
like
extens
chronic
gvhd
lower
lymphocyt
count
without
viremia
conclus
studi
demonstr
distinct
epidemiolog
hadv
korean
recipi
watch
monitor
hadv
viremia
recommend
hct
recipi
particularli
sever
lymphopenia
extens
chronic
gvhd
addit
studi
necessari
clarifi
relationship
hadv
type
clinic
sever
rate
viremia
author
report
conflict
interest
disclos
kang
kim
design
studi
kang
park
jong
min
kim
collect
sampl
perform
experi
kang
jong
min
kim
coordin
clinic
data
collect
statist
analys
kang
hee
jae
huh
analyz
sequenc
data
keon
hee
yoo
ki
woong
sung
koo
ki
nam
yong
lee
kim
supervis
data
collect
analysi
review
manuscript
kang
kim
wrote
paper
author
approv
final
submit
manuscript
